STROKE STATS Third leading cause of death 160 000 deaths a year 731 000 strokes a year 4 400 000 stroke survivors Leading cause of adult disability Source:

Slides:



Advertisements
Similar presentations
Mississippi State Plan for Heart Disease and Stroke Prevention and Control J. Clay Hays, Jr., M.D.
Advertisements

PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.
PAD A Call to Action. PAD: A Call to Action - What is peripheral arterial disease (PAD)? and why is it so dangerous? - Diagnosing PAD in the primary care.
The Diagnosis and Treatment of Peripheral Vascular Disease
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Journal Reading Myocardial infarction in young people Cardiol J 2009; 16, 4: 307–311 Cardiol J 2008; 15: 21–25 Presented by R 王郁菁 at ER conference.
Cholesterol quintile (mg/dL)
TM © 1999 Professional Postgraduate Services ® Diabetes and Cardiovascular Disease Epidemiology Clinical Trials Management Nathan Wong.
Morteza Naghavi, M.D. Founder Society for Heart Attack Prevention and Eradication (SHAPE) SHAPE Guidelines Prevention of Fatal Cardiovascular Events (Heart.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Risks & Prevention for Young Adults Cardiovascular Disease Kristen Hinners.
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
“Being ill makes me sad” Huon Gray National Clinical Director for Cardiac Care, NHS England Consultant Cardiologist, University Hospital of Southampton.
Lower levels of ADAMTS13 are associated with cardiovascular disease by Supakanya Lasom Master Degree Student of Medical Sciences, Bongers T.N, Bruijne.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
Coronary Artery Disease Angina Pectoris Unstable Angina Variant Angina Joseph D. Lynch, MD.
HILLSBOROUGH COUNTY SHERIFF’S DEPARTMENT Saving Our Law Officers From Sudden Death and Heart Attacks.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
By: David Tran, Mercer University, 2013 Pharm.D. Candidate Prececptor: Dr. Ali Rahimi Morbidity and Mortality Associated with Dyslipidemia.
Atherosclerosis Part 1 Atherosclerosis The general term for hardening of the arteries The most prevalent form of atherosclerosis is characterized by the.
Obesity, Metabolic Syndrome and Diabetes in Hispanics: implications on Cardiovascular Disease 2011 Eduardo de Marchena M.D., F.A.C.C., F.A.C.P. Professor.
Modern Management of Cholesterol in the High-Risk Patient.
Coronary Heart Disease The Magnitude of the Problem 2004 James T. Willerson, MD Medical Director: Texas Heart Institute Chief Of Cardiology: St. Luke’s.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Look Closer Improving understanding of the leading cause of heart attack and stroke.
Endothelial Progenitor Cells (EPCs)
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
HYPERLIPIDEMIA Applied Therapeutics Dr. Riyadh Mustafa Al-Salih.
Bi Qi Neurology Department of Beijing Anzhen Hospital of the Capital University of Medical Sciences ACS Complicated Cerebrovascular Disease—— How to Choose.
Impact of Diabetes on Cardiovascular Risk C.Richard Conti M.D. MACC Oct 16,2004 GWICC Beijing, PRC.
Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Cardiovascular Disease (CVD) Objectives: Describe the movement of blood through the cardiovascular system Discuss the prevalence of CVD Define the types.
Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Application of the Screening for Heart Attack Prevention.
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Clinical need for determination of vulnerable plaques
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Copyright © 2007 American Medical Association. All rights reserved.
Triglycerides Cholesterol HDL-C or N NIDDM N or or N IDDM.
ELIGIBILITY: MRC/BHF Heart Protection Study
AIM HIGH Niacin plus Statin to prevent vascular events
First time a CETP inhibitor shows reduction of serious CV events
FATS- Familial Atherosclerosis Treatment Study
TNT: Baseline and final LDL cholesterol levels
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
Section 5: Intervention and drug therapy
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Use of statins in the management of Unstable Angina
MACE rate among CAD severity groups (total 0
Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from.
FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.
Potential mechanisms whereby statins may reduce the risk of stroke
Baseline Characteristics of the Subjects*
Baseline Characteristics of the Patients – Part I
Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Genetic predisposition to CHD modifies the increased CHD risk associated with smoking (*) ORs adjusted for age, gender, total energy intake, alcohol intake,
Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,
The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%
Traditional cardiovascular risk factors can cause cardiac disease in patients with IIM. Systemic and local inflammation may either have a direct effect.
Presentation transcript:

STROKE STATS Third leading cause of death deaths a year strokes a year stroke survivors Leading cause of adult disability Source: Stroke Facts: 1999 NSA

Prevalence of stroke by age and sex United States: Heart Disease and Stroke Statistics – 2003 Update. Dallas, TX: AHA; 2002.

Adult Treatment Panel II National Cholesterol Education Program Circulation 1994; 89: Kannel WB. J. Cardiovascular Risk 1994; 1: Wilterdink et al., Arch Neurol 1992;49: Criqui et al., N. Engl. J. Med. 1992; 326: Initial event Increase in risk MI Stroke Myocardial infarction times (includes death) times ( includes TIA) Ischemic stroke times (includes angina and sudden death) 9 times PAD 4 times (includes fatal MI & other CHD death) times ( includes TIA) Peripheral vascular Cerebrovascular Coronary artery

Long-term risk of a cardiovascular event following a TIA Clark et al. J Neurol Neurosurg Psychiatry 2003;74: CV death, MI or stroke CHD death or MI Any stroke

Prevalence of IVUS-detected atherosclerotic coronary artery disease 21% 66% 75% 85% 91% >50 Prevalence (%) 262 healthy donor heart transplants Tuzcu EM. Circulation 2001;103:2705 Age (years)

68% 18% 14% Pre-MI Stenosis >70% 50-70% < 50% # patients Ambrose 1985 Little 1988 Nobuyoshi 1991 Giroud 1992 All E Falk, PK Shah, V Fuster. Circulation 1995;92:657 Stenosis severity by angiography of atherosclerotic disease preceding MI

Clinical presentation of atherosclerosis: Just the tip of the iceberg Clinical atherosclerosis CAD CVAPAD Subclinical Hyperinsulinemia Dyslipidemia Inflammation Platelet activation Hypercoagulable Endothelial dysfunction Oxidative stress